Impact of Cirrhotic Cardiomyopathy Diagnosed According to Different Criteria on Patients with Cirrhosis Awaiting Liver Transplantation: A Retrospective Cohort Study.
Cirrhosis
Heart failure
Hepatic Encephalopathy
Hepatorenal syndrome
Liver transplantation
Survival
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
08
10
2021
accepted:
23
01
2022
pubmed:
13
2
2022
medline:
26
10
2022
entrez:
12
2
2022
Statut:
ppublish
Résumé
Recently, the Cirrhotic Cardiomyopathy Consortium (Consortium) proposed criteria to replace the World Congress of Gastroenterology (WGO) criteria for cirrhotic cardiomyopathy (CCM) using contemporary echocardiography parameters. We assessed the impact of substituting WGO by Consortium criteria on the frequency of diagnosis and clinical outcomes in patients with cirrhosis awaiting liver transplantation (LT). Consecutive adults with cirrhosis approved for LT with echocardiography evaluation from January 2014 to December 2016 were screened. Patients with structural heart diseases were excluded. Two primary outcomes were: (1) frequency of CCM; (2) association of CCM with pre-transplant mortality. The secondary outcomes were pre-LT complications of acute kidney injury (AKI) and/or hepatic encephalopathy (HE), and post-LT mortality. Of 386 patients screened, 278 were included. 238 (85.6%) and 208 (74.8%) patients met Consortium and WGO criteria, respectively; 180 (64.7%) patients fulfilled both the criteria, while 12 (4.3%) patients had no evidence of CCM by either criterion. Pre-LT mortality rates in Consortium-CCM group were similar to the other groups (19.3% vs 20.2% vs 25.0%). The patients with advanced diastolic dysfunction (DD) per Consortium-CCM criteria had higher mortality than the other groups. The rates of pre-LT AKI/HE rates and post-LT mortality were similar in Consortium-CCM and WGO-CCM groups. The Consortium criteria do not impact the prevalence of CCM compared to WGO criteria and have similar predictive accuracy. Presence of advanced DD per the Consortium criteria increases the risk of pre-LT mortality and complications of AKI/HE. The patients with advanced DD could benefit from further monitoring and treatment.
Sections du résumé
BACKGROUND
Recently, the Cirrhotic Cardiomyopathy Consortium (Consortium) proposed criteria to replace the World Congress of Gastroenterology (WGO) criteria for cirrhotic cardiomyopathy (CCM) using contemporary echocardiography parameters. We assessed the impact of substituting WGO by Consortium criteria on the frequency of diagnosis and clinical outcomes in patients with cirrhosis awaiting liver transplantation (LT).
METHODS
Consecutive adults with cirrhosis approved for LT with echocardiography evaluation from January 2014 to December 2016 were screened. Patients with structural heart diseases were excluded. Two primary outcomes were: (1) frequency of CCM; (2) association of CCM with pre-transplant mortality. The secondary outcomes were pre-LT complications of acute kidney injury (AKI) and/or hepatic encephalopathy (HE), and post-LT mortality.
RESULTS
Of 386 patients screened, 278 were included. 238 (85.6%) and 208 (74.8%) patients met Consortium and WGO criteria, respectively; 180 (64.7%) patients fulfilled both the criteria, while 12 (4.3%) patients had no evidence of CCM by either criterion. Pre-LT mortality rates in Consortium-CCM group were similar to the other groups (19.3% vs 20.2% vs 25.0%). The patients with advanced diastolic dysfunction (DD) per Consortium-CCM criteria had higher mortality than the other groups. The rates of pre-LT AKI/HE rates and post-LT mortality were similar in Consortium-CCM and WGO-CCM groups.
CONCLUSION
The Consortium criteria do not impact the prevalence of CCM compared to WGO criteria and have similar predictive accuracy. Presence of advanced DD per the Consortium criteria increases the risk of pre-LT mortality and complications of AKI/HE. The patients with advanced DD could benefit from further monitoring and treatment.
Identifiants
pubmed: 35150344
doi: 10.1007/s10620-022-07412-z
pii: 10.1007/s10620-022-07412-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5315-5326Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Henriksen JH, Møller S. Cardiac and systemic haemodynamic complications of liver cirrhosis. Scand Cardiovasc J SCJ. 2009;43:218–225.
pubmed: 19145534
Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int Off J Int Assoc Study Liver. 2018;38:570–580.
Sampaio F, Lamata P, Bettencourt N, Alt SC, Ferreira N, Kowallick JT et al. Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2015;18:61.
Møller S, Danielsen KV, Wiese S, Hove JD, Bendtsen F. An update on cirrhotic cardiomyopathy. Expert Rev Gastroenterol Hepatol. 2019;13:497–505.
pubmed: 30802157
Wehmeyer MH, Heuer AJ, Benten D, Püschel K, Sydow K, Lohse AW et al. High rate of cardiac abnormalities in a postmortem analysis of patients suffering from liver cirrhosis. J Clin Gastroenterol. 2015;49:866–872.
pubmed: 25856382
Wroński J, Fiedor P, Kwolczak M, Górnicka B. Retrospective analysis of liver cirrhosis influence on heart walls thickness. Pathol Res Pract. 2015;211:145–149.
pubmed: 25468291
Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: Pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11:177–186.
pubmed: 24217347
Stundiene I, Sarnelyte J, Norkute A, Aidietiene S, Liakina V, Masalaite L et al. Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review. World J Gastroenterol. 2019;25:4779–4795.
pubmed: 31528101
pmcid: 6718042
Dadhich S, Goswami A, Jain VK, Gahlot A, Kulamarva G, Bhargava N. Cardiac dysfunction in cirrhotic portal hypertension with or without ascites. Ann Gastroenterol. 2014;27:244–249.
pubmed: 24974920
pmcid: 4073021
Somani PO, Contractor Q, Chaurasia AS, Rathi PM. Diastolic dysfunction characterizes cirrhotic cardiomyopathy. Indian Heart J. 2014;66:649–655.
pubmed: 25634400
pmcid: 4310959
Cesari M, Frigo AC, Tonon M, Angeli P. Cardiovascular predictors of death in patients with cirrhosis. Hepatology. 2018;68:215–223.
pubmed: 28902431
Mittal C, Qureshi W, Singla S, Ahmad U, Huang MA. Pre-transplant left ventricular diastolic dysfunction is associated with post transplant acute graft rejection and graft failure. Dig Dis Sci. 2014;59:674–680.
pubmed: 24323177
Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C et al. LEFT ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58:51–57.
pubmed: 22989573
Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;57:268–278.
pubmed: 18192456
Ruíz-del-Árbol L, Achécar L, Serradilla R, Rodríguez-Gandía MA, Rivero M, Garrido E et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology. 2013;58:1732–1741.
pubmed: 23703953
Izzy M, Oh J, Watt KD. Cirrhotic cardiomyopathy after transplantation: neither the transient nor innocent bystander. Hepatol Baltim Md. 2018;68:2008–2015.
Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK et al. Redefining cirrhotic cardiomyopathy for the modern Era. Hepatology. 2020;71:334–345.
pubmed: 31342529
Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G et al. Cirrhotic cardiomyopathy predicts posttransplant cardiovascular disease: revelations of the new diagnostic criteria. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2021;27:876–886.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28:53.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29:277–314.
pubmed: 27037982
Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, et al. Redefining Cirrhotic Cardiomyopathy For The Modern Era. Hepatol Baltim Md. 2019
Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs. 2019;79:5–9.
pubmed: 30706420
pmcid: 6416238
Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531–537.
pubmed: 25631669
Razpotnik M, Bota S, Wimmer P, Hackl M, Lesnik G, Alber H et al. The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. Liver Int Off J Int Assoc Study Liver. 2021;41:1058–1069.
Cesari M, Frigo AC, Piano S, Angeli P. Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification. Clin Exp Hepatol. 2021;7:270–277.
pubmed: 34712828
pmcid: 8527346
Pellicori P, Torromeo C, Calicchia A, Ruffa A, Di Iorio M, Cleland JGF et al. Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. Clin Res Cardiol. 2013;102:859–864.
pubmed: 23995321
Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58:51–57.
pubmed: 22989573
Jansen C, Cox A, Schueler R, Schneider M, Lehmann J, Praktiknjo M et al. Increased myocardial contractility identifies patients with decompensated cirrhosis requiring liver transplantation. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2018;24:15–25.
Jansen C, Schröder A, Schueler R, Lehmann J, Praktiknjo M, Uschner FE et al. Left ventricular longitudinal contractility predicts acute-on-chronic liver failure development and mortality after transjugular intrahepatic portosystemic shunt. Hepatol Commun. 2019;3:340–347.
pubmed: 30984902
pmcid: 6444053
Premkumar M, Devurgowda D, Vyas T, Shasthry SM, Khumuckham JS, Goyal R et al. Left ventricular diastolic dysfunction is associated with renal dysfunction, poor survival and low health related quality of life in cirrhosis. J Clin Exp Hepatol. 2019;9:324–333.
pubmed: 31360025
Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva A-P, Valente J et al. Systolic dysfunction and diastolic dysfunction do not influence medium-term prognosis in patients with cirrhosis. Eur J Intern Med. 2014;25:241–246.
pubmed: 24485543
Kazory A, Ronco C. Hepatorenal syndrome or hepatocardiorenal syndrome: Revisiting basic concepts in view of emerging data. Cardiorenal Med. 2019;9:1–7.
pubmed: 30223273
Arroyo V, Fernández J. Relationship between systemic hemodynamics, renal dysfunction, and fluid retention in cirrhosis. Clin Liver Dis. 2013;2:120–122.
Kazory A, Elkayam U. Cardiorenal interactions in acute decompensated heart failure: contemporary concepts facing emerging controversies. J Card Fail. 2014;20:1004–1011.
pubmed: 25230240
Kapoor N, Mehta V, Singh B, Karna R, Kumar S, Kar P. Prevalence of cirrhotic cardiomyopathy and its relationship with serum pro-brain natriuretic peptide, hepatorenal syndrome, spontaneous bacterial peritonitis, and mortality. Indian J Gastroenterol Off J Indian Soc Gastroenterol. 2020
Sonny A, Ibrahim A, Schuster A, Jaber WA, Cywinski JB. Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. Clin Transplant. 2016;30:986–993.
pubmed: 27292629
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–870.
pubmed: 29792299
pmcid: 6202181